###MEDLINE:20452467

High-dose	I-protein
growth	I-protein
hormone	I-protein
does	O
not	I-protein
affect	O
proinflammatory	O
cytokine	O
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-6	O
,	O
and	I-protein
interferon-gamma	B-protein
)	O
release	I-protein
from	I-protein
activated	O
peripheral	O
blood	O
mononuclear	O
cells	I-protein
or	I-protein
after	O
minimal	O
to	I-protein
moderate	O
surgical	O
stress	O
.	O

High-dose	O
GH	O
therapy	O
,	O
with	I-protein
GH	O
doses	O
10-20	O
times	O
the	I-protein
normal	O
replacement	I-protein
dose	O
for	I-protein
GH-deficient	O
adults	O
,	O
has	O
been	O
used	O
as	O
an	I-protein
anti-catabolic	O
agent	O
in	I-protein
a	I-protein
number	I-protein
of	I-protein
different	O
patient	O
groups	O
.	O

A	O
recent	O
study	O
,	O
however	O
,	O
has	O
shown	O
an	I-protein
increase	O
in	I-protein
mortality	B-protein
in	I-protein
critically	O
ill	O
patients	O
treated	O
with	I-protein
high-dose	O
GH	O
.	O

The	O
increased	I-protein
mortality	B-protein
was	O
associated	I-protein
with	I-protein
multiorgan	O
failure	I-protein
,	O
septic	O
shock	I-protein
,	O
and	I-protein
uncontrolled	O
infection	I-protein
,	O
suggesting	O
that	O
GH	B-protein
may	O
have	O
altered	I-protein
the	I-protein
immune	O
response	I-protein
.	O

The	O
GH	B-protein
receptor	I-protein
and	I-protein
GH	B-protein
are	O
both	O
expressed	O
in	I-protein
peripheral	O
blood	O
mononuclear	O
cells	I-protein
(	O
PBMCs	O
)	O
;	O
thus	O
,	O
GH	O
could	O
act	O
as	O
either	O
an	I-protein
endocrine	I-protein
or	I-protein
an	I-protein
autocrine	B-protein
modulator	O
of	I-protein
the	I-protein
immune	O
response	I-protein
.	O

We	O
have	O
examined	O
the	I-protein
hypothesis	O
that	O
high-dose	O
GH	O
therapy	O
may	O
induce	O
proinflammatory	B-protein
cytokines	I-protein
,	O
which	O
are	O
implicated	O
in	I-protein
septic	O
shock	I-protein
.	O

To	O
do	O
this	O
we	O
measured	O
cytokine	O
production	I-protein
by	I-protein
PBMCs	O
incubated	O
in	I-protein
conditions	O
that	O
simulated	O
high-dose	O
GH	O
therapy	O
,	O
and	I-protein
we	O
measured	O
cytokine	O
levels	I-protein
in	I-protein
patients	O
undergoing	O
laparoscopic	O
cholecystectomy	O
who	O
were	O
randomized	O
to	I-protein
receive	O
either	O
high-dose	O
GH	O
therapy	O
(	O
13	I-protein
IU/m2	O
x	I-protein
day	O
)	O
or	I-protein
placebo	O
.	O

To	O
confirm	O
the	I-protein
biological	O
activity	I-protein
of	I-protein
GH	O
in	I-protein
our	O
cell	O
culture	O
system	I-protein
we	O
used	O
a	I-protein
Stat5	B-protein
functional	O
assay	O
.	O

In	O
this	O
assay	O
GH	O
induced	I-protein
a	I-protein
bell-shaped	O
curve	O
,	O
with	I-protein
a	I-protein
maximal	O
response	I-protein
at	I-protein
GH	O
levels	I-protein
between	O
100-1	O
,	O
000	O
ng/mL	O
.	O

PBMCs	O
from	I-protein
healthy	O
volunteers	O
were	O
incubated	O
with	I-protein
GH	O
in	I-protein
doses	O
from	I-protein
1-1	I-protein
,	O
000	O
ng/mL	O
for	I-protein
6-72	O
h	I-protein
under	O
resting	O
conditions	O
and	I-protein
after	O
activation	I-protein
with	I-protein
endotoxin	O
and	I-protein
the	I-protein
mixed	O
lymphocyte	O
reaction	I-protein
.	O

Studies	O
were	O
repeated	O
with	I-protein
PBMCs	O
from	I-protein
six	O
individuals	O
using	O
a	I-protein
GH	O
dose	O
of	I-protein
100	I-protein
ng/mL	O
(	O
the	I-protein
level	I-protein
of	I-protein
GH	O
found	O
after	O
high-dose	O
GH	O
therapy	O
)	O
and	I-protein
an	I-protein
endotoxin	O
dose	O
that	O
gave	O
a	I-protein
submaximal	O
response	I-protein
(	O
0.01	O
ng/mL	O
)	O
.	O

GH	O
had	O
no	I-protein
effect	O
on	I-protein
cell	O
proliferation	I-protein
or	I-protein
the	I-protein
production	I-protein
of	I-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNFalpha	B-protein
)	O
,	O
interleukin-6	O
(	O
IL-6	B-protein
)	O
,	O
or	I-protein
interferon-gamma	B-protein
(	O
IFNgamma	B-protein
)	O
.	O

In	O
patients	O
undergoing	O
laparoscopic	O
cholecystectomy	O
there	O
was	O
a	I-protein
time-related	O
effect	O
of	I-protein
surgery	O
on	I-protein
cytokine	O
levels	I-protein
.	O

There	O
was	O
a	I-protein
rise	O
in	I-protein
IL-6	B-protein
and	I-protein
a	I-protein
fall	O
in	I-protein
TNFalpha	B-protein
at	I-protein
24	I-protein
h	I-protein
after	O
surgery	O
;	O
however	O
,	O
high-dose	O
GH	O
therapy	O
had	O
no	I-protein
effect	O
on	I-protein
the	I-protein
cytokine	O
response	I-protein
.	O

We	O
considered	O
the	I-protein
possibility	O
that	O
endogenous	O
GH	O
production	I-protein
by	I-protein
PBMCs	O
could	O
influence	O
the	I-protein
cytokine	O
response	I-protein
in	I-protein
activated	O
PBMCs	O
;	O
however	O
,	O
incubation	O
of	I-protein
PBMCs	O
in	I-protein
the	I-protein
presence	O
of	I-protein
the	I-protein
GH	B-protein
receptor	I-protein
antagonist	O
,	O
B2036	O
,	O
had	O
no	I-protein
effect	O
on	I-protein
TNFalpha	B-protein
,	O
IL-6	B-protein
,	O
or	I-protein
IFNgamma	B-protein
production	I-protein
by	I-protein
PBMCs	O
in	I-protein
either	O
the	I-protein
mixed	O
lymphocyte	O
reaction	I-protein
or	I-protein
when	O
activated	O
by	I-protein
endotoxin	O
.	O

These	O
results	O
suggest	O
that	O
high-dose	O
GH	O
therapy	O
does	O
not	I-protein
alter	O
the	I-protein
proinflammatory	O
cytokine	O
response	I-protein
to	I-protein
surgery	O
or	I-protein
endotoxin	O
.	O

The	O
results	O
do	O
not	I-protein
exclude	O
an	I-protein
effect	O
of	I-protein
GH	O
on	I-protein
the	I-protein
immune	O
response	I-protein
,	O
but	O
they	O
suggest	O
that	O
the	I-protein
mortality	B-protein
seen	O
in	I-protein
critically	O
ill	O
patients	O
may	O
be	O
due	I-protein
to	I-protein
factors	I-protein
other	O
than	I-protein
immune	O
modulation	O
.	O

###MEDLINE:20564267

Interaction	O
between	O
interferon	B-protein
consensus	I-protein
sequence-binding	I-protein
protein	I-protein
and	I-protein
COP9/signalosome	I-protein
subunit	I-protein
CSN2	B-protein
(	O
Trip15	O
)	O
.	O

A	O
possible	O
link	I-protein
between	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
signaling	O
and	I-protein
the	I-protein
COP9/signalosome	O
.	O

Interferon	I-protein
consensus	I-protein
sequence-binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
is	O
a	I-protein
member	I-protein
of	I-protein
the	I-protein
interferon	B-protein
regulatory	I-protein
factors	I-protein
(	O
IRF	B-protein
)	O
that	O
has	O
a	I-protein
pivotal	O
role	O
in	I-protein
mediating	I-protein
resistance	O
to	I-protein
pathogenic	O
infections	O
in	I-protein
mice	O
and	I-protein
in	I-protein
promoting	I-protein
the	I-protein
differentiation	I-protein
of	I-protein
myeloid	O
cells	I-protein
.	O

ICSBP	B-protein
exerts	O
some	O
of	I-protein
its	O
transcriptional	O
activities	O
via	I-protein
association	I-protein
with	I-protein
other	O
factors	I-protein
that	O
enable	O
its	O
binding	I-protein
to	I-protein
a	I-protein
variety	O
of	I-protein
promoters	O
containing	I-protein
DNA	O
composite	O
elements	O
.	O

These	O
interactions	O
are	O
mediated	I-protein
through	I-protein
a	I-protein
specific	I-protein
COOH-terminal	I-protein
domain	I-protein
termed	O
IAD	O
(	O
IRF	B-protein
association	I-protein
domain	I-protein
)	O
.	O

To	O
gain	O
a	I-protein
broader	O
insight	O
of	I-protein
the	I-protein
capacity	O
of	I-protein
ICSBP	B-protein
to	I-protein
interact	O
with	I-protein
other	O
factors	I-protein
,	O
yeast	O
two-hybrid	O
screens	O
were	O
performed	O
using	O
ICSBP-IAD	B-protein
as	O
a	I-protein
bait	O
against	I-protein
a	I-protein
B-cell	O
cDNA	I-protein
library	O
.	O

Trip15	O
was	O
identified	I-protein
as	O
a	I-protein
specific	I-protein
interacting	I-protein
factor	I-protein
with	I-protein
ICSBP	B-protein
in	I-protein
yeast	O
cells	I-protein
,	O
which	O
was	O
also	O
confirmed	O
by	I-protein
in	I-protein
vitro	O
glutathione	O
S-transferase	I-protein
pull-down	O
assays	O
and	I-protein
by	I-protein
coimmunoprecipitation	O
studies	O
in	I-protein
COS7	O
cells	I-protein
.	O

Trip15	O
was	O
recently	O
identified	I-protein
as	O
a	I-protein
component	O
of	I-protein
the	I-protein
COP9/signalosome	O
(	O
CSN	B-protein
)	O
complex	I-protein
composed	O
of	I-protein
eight	O
evolutionary	I-protein
conserved	O
subunits	I-protein
and	I-protein
thus	O
termed	O
CSN2	B-protein
.	O

This	O
complex	I-protein
has	O
a	I-protein
role	O
in	I-protein
cell-signaling	O
processes	O
,	O
which	O
is	O
manifested	O
by	I-protein
its	O
associated	I-protein
novel	O
kinase	O
activity	I-protein
and	I-protein
by	I-protein
the	I-protein
involvement	I-protein
of	I-protein
its	O
subunits	I-protein
in	I-protein
regulating	O
multiple	O
cell-signaling	O
pathways	O
and	I-protein
cell-cycle	O
progression	I-protein
.	O

We	O
show	O
that	O
in	I-protein
vitro	O
association	I-protein
of	I-protein
ICSBP	B-protein
with	I-protein
the	I-protein
CSN	B-protein
leads	O
to	I-protein
phosphorylation	I-protein
of	I-protein
ICSBP	B-protein
at	I-protein
a	I-protein
unique	I-protein
serine	O
residue	I-protein
within	B-protein
its	O
IAD	O
.	O

The	O
phosphorylated	B-protein
residue	I-protein
is	O
essential	O
for	I-protein
efficient	O
association	I-protein
with	I-protein
IRF-1	B-protein
and	I-protein
thus	O
for	I-protein
the	I-protein
repressor	O
activity	I-protein
of	I-protein
ICSBP	B-protein
exerted	O
on	I-protein
IRF-1	B-protein
.	O

This	O
suggests	O
that	O
the	I-protein
CSN	O
has	O
a	I-protein
role	O
in	I-protein
integrating	O
incoming	O
signals	I-protein
that	O
affect	O
the	I-protein
transcriptional	O
activity	I-protein
of	I-protein
ICSBP	B-protein
.	O

###MEDLINE:20434840

Intrathymic	O
T	O
cell	O
development	O
and	I-protein
selection	O
proceeds	O
normally	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
glucocorticoid	B-protein
receptor	I-protein
signaling	O
.	O

Glucocorticoids	O
are	O
believed	O
to	I-protein
play	O
a	I-protein
role	O
in	I-protein
T	O
cell	O
development	O
and	I-protein
selection	O
,	O
although	O
their	O
precise	O
function	I-protein
is	O
controversial	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
-deficient	O
mice	O
were	O
used	O
to	I-protein
directly	O
investigate	O
this	O
problem	O
.	O

GR-deficient	O
thymocytes	O
were	O
resistant	I-protein
to	I-protein
dexamethasone-mediated	O
apoptosis	O
,	O
confirming	O
the	I-protein
absence	I-protein
of	I-protein
glucocorticoid	O
responsiveness	O
.	O

An	O
absence	I-protein
of	I-protein
GR	B-protein
signaling	O
had	O
no	I-protein
impact	O
on	I-protein
thymocyte	B-protein
development	O
either	O
in	I-protein
vivo	O
or	I-protein
in	I-protein
vitro	O
.	O

T	O
cell	O
differentiation	I-protein
,	O
including	I-protein
positive	I-protein
selection	O
,	O
was	O
normal	O
as	O
assessed	O
by	I-protein
normal	O
development	O
of	I-protein
CD4+CD8+	O
,	O
alphabetaTCR+CD4+	O
,	O
and	I-protein
alphabetaTCR+CD8+	O
thymocytes	O
.	O

Negative	O
selection	O
,	O
mediated	I-protein
by	I-protein
the	I-protein
superantigen	O
staphylococcal	B-protein
enterotoxin	I-protein
B	O
(	O
SEB	B-protein
)	O
,	O
or	I-protein
anti-CD3/CD28	O
,	O
was	O
also	O
normal	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
GR	B-protein
signaling	O
.	O

In	O
contrast	O
to	I-protein
earlier	O
reports	O
,	O
these	O
data	O
demonstrate	O
that	O
GR	B-protein
signaling	O
is	O
not	I-protein
essential	O
for	I-protein
intrathymic	O
T	O
cell	O
development	O
or	I-protein
selection	O
.	O

###MEDLINE:20430060

Rapid	O
polarization	O
of	I-protein
Th2	O
cells	I-protein
during	I-protein
induction	I-protein
of	I-protein
antigen-specific	B-protein
IgE	I-protein
antibodies	I-protein
in	I-protein
vitro	O
.	O

BACKGROUND	O
:	O
Type	I-protein
2	I-protein
T-helper	O
cells	I-protein
(	O
Th2	O
)	O
are	O
involved	I-protein
in	I-protein
the	I-protein
regulation	I-protein
of	I-protein
the	I-protein
humoral	O
immune	O
response	I-protein
against	I-protein
antigens	I-protein
and	I-protein
allergens	O
and	I-protein
directly	O
affect	O
which	O
isotype	I-protein
will	O
be	O
produced	O
.	O

The	O
mechanism	O
that	O
regulates	O
antigen-specific	O
IgE	O
secretion	O
and	I-protein
immune	O
deviation	O
is	O
still	O
not	I-protein
known	O
.	O

OBJECTIVES	O
:	O
To	O
delineate	O
mechanisms	O
behind	O
antigen-specific	O
IgE	O
secretion	O
we	O
have	O
used	O
in	I-protein
vitro	O
immunization	O
and	I-protein
focused	O
on	I-protein
T-cell	O
phenotype	O
and	I-protein
the	I-protein
activation	I-protein
status	I-protein
of	I-protein
the	I-protein
transcription	B-protein
factor	I-protein
NFkappaB	I-protein
.	O

METHODS	O
:	O
Peripheral	O
blood	O
lymphocytes	O
(	O
PBMC	O
)	O
from	I-protein
seronegative	O
donors	O
were	O
immunized	O
in	I-protein
vitro	O
with	I-protein
a	I-protein
peptide	O
consisting	O
of	I-protein
both	O
a	I-protein
T-cell	O
and	I-protein
a	I-protein
B-cell	O
epitope	I-protein
.	O

RESULTS	O
:	O
Antigen-specific	O
IgE	B-protein
antibodies	I-protein
could	O
be	O
detected	O
after	O
a	I-protein
primary	O
immunization	O
,	O
during	I-protein
which	O
T-helper	O
cells	I-protein
secreted	O
type	B-protein
2	I-protein
cytokines	I-protein
.	O

Specific	B-protein
IgE	B-protein
was	O
also	O
detected	O
in	I-protein
the	I-protein
secondary	O
immunization	O
,	O
but	O
due	I-protein
to	I-protein
a	I-protein
rapid	O
polarization	O
from	I-protein
Th2	O
to	I-protein
Th1	O
phenotype	O
,	O
exogenous	O
IL-4	B-protein
was	O
required	O
for	I-protein
the	I-protein
specific	I-protein
IgE	O
secretion	O
.	O

Analysis	O
of	I-protein
NFkappaB	O
activation	I-protein
in	I-protein
B	O
and	I-protein
T	O
cells	I-protein
during	I-protein
primary	O
and	I-protein
secondary	O
immunization	O
showed	O
that	O
NFkappaB	B-protein
could	O
be	O
detected	O
in	I-protein
both	O
B	O
and	I-protein
T	O
cells	I-protein
during	I-protein
primary	O
immunization	O
,	O
but	O
was	O
dependent	I-protein
on	I-protein
exogenous	O
IL-4	B-protein
in	I-protein
the	I-protein
secondary	O
immunization	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	I-protein
first	O
evidence	O
of	I-protein
antigen-specific	O
IgE	O
induction	I-protein
in	I-protein
vitro	O
using	O
naive	O
B	O
cells	I-protein
,	O
demonstrating	O
the	I-protein
involvement	I-protein
of	I-protein
T-helper	O
cell	O
phenotype	O
and	I-protein
NFkappaB	B-protein
and	I-protein
demonstrates	O
the	I-protein
usefulness	O
of	I-protein
in	I-protein
vitro	O
cultures	O
to	I-protein
study	O
the	I-protein
effect	O
of	I-protein
antigens	I-protein
on	I-protein
human	O
immunocytes	O
.	O

###MEDLINE:20420778

Pulmonary	B-protein
function	I-protein
changes	O
and	I-protein
increased	I-protein
Th-2	B-protein
cytokine	I-protein
expression	I-protein
and	I-protein
nuclear	O
factor	I-protein
kB	O
activation	I-protein
in	I-protein
the	I-protein
lung	O
after	O
sensitization	O
and	I-protein
allergen	O
challenge	O
in	I-protein
brown	I-protein
Norway	O
rats	O
.	O

BACKGROUND	O
:	O
Our	O
purpose	O
was	O
to	I-protein
evaluate	O
the	I-protein
expression	I-protein
of	I-protein
Th-1	O
and	I-protein
Th-2	O
related	O
cytokine	O
mRNA	O
and	I-protein
nuclear	B-protein
factor	I-protein
(	O
NF	O
)	O
kB	O
in	I-protein
the	I-protein
lung	O
tissue	O
of	I-protein
ovalbumin	I-protein
(	O
OA	O
)	O
sensitized	O
brown	I-protein
Norway	O
rats	O
(	O
BNR	O
)	O
.	O

We	O
also	O
evaluated	O
the	I-protein
correlation	O
between	O
bronchial	O
hyperreactivity	O
(	O
BHR	O
)	O
and	I-protein
eosinophils	O
with	I-protein
cytokine	O
mRNA	O
expression	I-protein
.	O

METHODS	O
:	O
Eight	O
BNR	O
(	O
weight	I-protein
range	O
250-350	O
g	I-protein
)	O
were	O
sensitized	O
by	I-protein
inhaled	O
OA	O
(	O
group	I-protein
I	I-protein
)	O
with	I-protein
a	I-protein
1-week	O
interval	O
between	O
and	I-protein
then	O
provoked	O
with	I-protein
OA	O
1	I-protein
week	O
later	O
.	O

Pulmonary	B-protein
function	I-protein
tests	O
(	O
PFT	O
)	O
were	O
performed	O
at	I-protein
baseline	O
and	I-protein
24	I-protein
h	I-protein
after	O
acetylcholine	I-protein
challenge	O
.	O

Eight	O
weight-matched	O
normal	O
BNR	O
served	O
as	O
controls	O
(	O
group	I-protein
II	I-protein
)	O
.	O

All	O
animals	O
were	O
anesthetized	O
,	O
paralyzed	O
with	I-protein
gallamine	O
,	O
and	I-protein
ventilated	O
via	I-protein
tracheostomy	O
.	O

They	O
were	O
given	O
varying	O
doses	O
of	I-protein
acetylcholine	I-protein
(	O
25	I-protein
,	O
50	I-protein
,	O
75	I-protein
,	O
100	I-protein
microg/kg	O
)	O
injected	O
through	I-protein
a	I-protein
jugular	O
venous	I-protein
catheter	O
.	O

Five	O
seconds	O
after	O
acetylcholine	I-protein
injections	O
,	O
PFTs	O
were	O
performed	O
,	O
including	I-protein
a	I-protein
maximal	O
forced	O
expiratory	O
maneuver	O
(	O
MFEM	O
)	O
,	O
airway	I-protein
opening	O
pressure	I-protein
(	O
P	O
(	O
ao	O
)	O
)	O
at	I-protein
tidal	O
breathing	O
and	I-protein
total	O
dynamic	O
lung	O
compliance	O
(	O
C	O
(	O
dyn	O
)	O
)	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	B-protein
)	O
was	O
then	O
performed	O
with	I-protein
20	I-protein
ml	O
normal	O
saline	O
divided	O
into	O
two	O
doses	O
.	O

Thereafter	O
,	O
the	I-protein
lungs	O
were	O
removed	O
and	I-protein
examined	O
histologically	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	I-protein
lung	O
tissue	O
samples	O
and	I-protein
reverse-transcriptase	O
polymerase	O
chain	I-protein
reaction	I-protein
was	O
performed	O
using	O
primers	O
for	I-protein
mRNA	O
of	I-protein
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-10	B-protein
,	O
interferon-gamma	B-protein
(	O
IFNr	O
)	O
and	I-protein
beta-actine	O
.	O

RESULTS	O
:	O
Group	I-protein
I	I-protein
OA	O
treated	O
rats	O
had	O
typical	I-protein
airway	I-protein
obstruction	I-protein
on	I-protein
PFTs	O
and	I-protein
airway	I-protein
inflammation	O
on	I-protein
histological	O
examination	O
.	O

Ratios	O
of	I-protein
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-10	B-protein
and	I-protein
inducible	B-protein
nitric	B-protein
oxide	I-protein
synthase	I-protein
(	O
iNOS	I-protein
)	O
mRNA	O
levels	I-protein
to	I-protein
beta-actine	O
as	O
measured	O
by	I-protein
densitometry	O
were	O
significantly	O
lower	I-protein
in	I-protein
controls	O
than	I-protein
in	I-protein
OA-sensitized	O
rats	O
.	O

The	O
IFNr	O
mRNA	O
to	I-protein
beta-actin	O
ratio	O
was	O
significantly	O
reduced	O
in	I-protein
OA-sensitized	O
rats	O
.	O

Group	I-protein
I	I-protein
demonstrated	O
a	I-protein
band	I-protein
shift	O
when	O
compared	O
with	I-protein
group	I-protein
II	I-protein
in	I-protein
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
for	I-protein
NF-kB	B-protein
indicating	O
increased	I-protein
activation	I-protein
of	I-protein
this	O
transcription	B-protein
factor	I-protein
.	O

CONCLUSION	O
:	O
Th-2	O
related	O
cytokine	O
mRNA	O
was	O
increased	I-protein
but	O
Th-1	O
related	O
cytokine	O
mRNA	O
was	O
decreased	O
in	I-protein
OA-sensitized	O
BNR	O
.	O

An	O
increased	I-protein
level	I-protein
of	I-protein
Th-2	O
related	O
cytokine	O
mRNA	O
correlated	O
with	I-protein
decreased	O
airflow	O
and	I-protein
inflammatory	O
changes	O
.	O

These	O
results	O
demonstrate	O
the	I-protein
value	O
of	I-protein
the	I-protein
BNR	O
model	I-protein
for	I-protein
studying	O
allergic	O
asthma	I-protein
at	I-protein
the	I-protein
molecular	I-protein
level	I-protein
.	O

###MEDLINE:20413477

3	O
,	O
5-Bis	O
(	O
trifluoromethyl	O
)	O
pyrazoles	O
:	O
a	I-protein
novel	O
class	O
of	I-protein
NFAT	B-protein
transcription	I-protein
factor	I-protein
regulator	I-protein
.	O

A	O
series	O
of	I-protein
bis	B-protein
(	O
trifluoromethyl	O
)	O
pyrazoles	O
(	O
BTPs	O
)	O
has	O
been	O
found	O
to	I-protein
be	O
a	I-protein
novel	O
inhibitor	O
of	I-protein
cytokine	O
production	I-protein
.	O

Identified	O
initially	O
as	O
inhibitors	I-protein
of	I-protein
IL-2	B-protein
synthesis	I-protein
,	O
the	I-protein
BTPs	O
have	O
been	O
optimized	O
in	I-protein
this	O
regard	O
and	I-protein
even	O
inhibit	O
IL-2	B-protein
production	I-protein
with	I-protein
a	I-protein
10-fold	O
enhancement	O
over	O
cyclosporine	O
in	I-protein
an	I-protein
ex	O
vivo	O
assay	O
.	O

Additionally	O
,	O
the	I-protein
BTPs	O
show	O
inhibition	O
of	I-protein
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-8	B-protein
,	O
and	I-protein
eotaxin	B-protein
production	I-protein
.	O

Unlike	O
the	I-protein
IL-2	B-protein
inhibitors	I-protein
,	O
cyclosporine	O
and	I-protein
FK506	B-protein
,	O
the	I-protein
BTPs	O
do	O
not	I-protein
directly	O
inhibit	O
the	I-protein
dephosphorylation	O
of	I-protein
NFAT	B-protein
by	I-protein
calcineurin	B-protein
.	O

###MEDLINE:20406551

A	O
repression-derepression	O
mechanism	O
regulating	O
the	I-protein
transcription	O
of	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
in	I-protein
primary	O
T	O
cells	I-protein
.	O

BACKGROUND	O
:	O
Despite	O
some	O
controversy	O
regarding	O
the	I-protein
preferential	O
infection	I-protein
and	I-protein
replication	O
of	I-protein
human	O
immunodeficiency	I-protein
virus	I-protein
type	O
1	I-protein
(	O
HIV-1	O
)	O
,	O
it	O
appears	O
that	O
primary	O
T	O
lymphocytes	O
,	O
in	I-protein
their	O
quiescent	O
state	I-protein
,	O
are	O
nonpermissive	O
for	I-protein
viral	O
expression	I-protein
and	I-protein
propagation	O
.	O

Massive	O
activation	I-protein
of	I-protein
viral	O
gene	O
expression	I-protein
occurs	O
only	I-protein
when	O
the	I-protein
host	O
lymphocyte	O
is	O
activated	O
.	O

These	O
observations	O
prompted	O
us	O
to	I-protein
investigate	O
the	I-protein
transcriptional	O
regulation	I-protein
of	I-protein
HIV-1	O
in	I-protein
resting	O
or	I-protein
activated	O
T	O
cells	I-protein
that	O
were	O
isolated	I-protein
from	I-protein
cord	O
blood	O
or	I-protein
adult	O
peripheral	O
blood	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
To	O
this	O
end	I-protein
,	O
we	O
employed	O
cellular	O
purification	O
and	I-protein
phenotyping	O
techniques	O
,	O
in	I-protein
vitro	O
protein-DNA	O
binding	I-protein
studies	O
,	O
functional	O
transactivation	O
assays	O
using	O
proteins	I-protein
isolated	I-protein
from	I-protein
cord	O
blood	O
or	I-protein
adult	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
and	I-protein
transfection	O
experiments	O
in	I-protein
primary	O
T	O
cells	I-protein
.	O

RESULTS	O
:	O
We	O
showed	O
that	O
transcription	O
from	I-protein
the	I-protein
HIV-1	O
long	I-protein
terminal	O
repeat	I-protein
is	O
repressed	I-protein
in	I-protein
resting	O
naive	O
T	O
lymphocytes	O
;	O
whereas	O
,	O
mitogenically	O
stimulated	O
CD4+	O
cells	I-protein
form	I-protein
an	I-protein
activator	O
that	O
derepresses	O
transcription	O
.	O

Negative	O
and	I-protein
positive	I-protein
regulation	I-protein
act	O
through	I-protein
a	I-protein
repressor-activator	O
target	O
sequence	I-protein
(	O
RATS	O
)	O
,	O
which	O
shares	O
homology	I-protein
with	I-protein
the	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
purine-rich	B-protein
response	I-protein
element	I-protein
,	O
through	I-protein
the	I-protein
adjacent	I-protein
binding	I-protein
site	I-protein
of	I-protein
the	I-protein
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
and	I-protein
weakly	B-protein
,	O
through	I-protein
the	I-protein
KB	O
region	O
.	O

CONCLUSIONS	O
:	O
This	O
regulation	I-protein
exerted	O
by	I-protein
cellular	B-protein
transcription	I-protein
factors	I-protein
can	O
account	O
for	I-protein
several	I-protein
important	O
features	I-protein
of	I-protein
HIV-1	O
expression	I-protein
in	I-protein
primary	O
CD4+	O
cells	I-protein
.	O

Tight	O
repression	I-protein
in	I-protein
resting	O
naive	O
T	O
helper	I-protein
cells	I-protein
may	O
be	O
a	I-protein
main	O
cause	O
of	I-protein
viral	O
latency	O
and	I-protein
transcriptional	O
activation	I-protein
accounts	O
for	I-protein
massive	O
viral	O
production	I-protein
in	I-protein
activated	O
T	O
lymphocytes	O
.	O

###MEDLINE:20405655

Involvement	O
of	I-protein
lipopolysaccharide	B-protein
binding	I-protein
protein	I-protein
,	O
CD14	B-protein
,	O
and	I-protein
Toll-like	B-protein
receptors	I-protein
in	I-protein
the	I-protein
initiation	I-protein
of	I-protein
innate	O
immune	O
responses	O
by	I-protein
Treponema	O
glycolipids	O
.	O

Culture	O
supernatants	O
from	I-protein
Treponema	O
maltophilum	O
associated	I-protein
with	I-protein
periodontitis	O
in	I-protein
humans	O
and	I-protein
Treponema	O
brennaborense	O
found	O
in	I-protein
a	I-protein
bovine	I-protein
cattle	O
disease	I-protein
accompanied	O
with	I-protein
cachexia	O
caused	O
a	I-protein
dose-dependent	O
TNF-alpha	B-protein
synthesis	I-protein
in	I-protein
human	O
monocytes	O
increasing	O
with	I-protein
culture	O
time	O
.	O

This	O
activity	I-protein
could	O
be	O
reduced	O
significantly	O
by	I-protein
blocking	O
the	I-protein
CD14	B-protein
-part	O
of	I-protein
the	I-protein
LPS	B-protein
receptor	O
using	O
the	I-protein
My	O
4	I-protein
mAb	O
and	I-protein
by	I-protein
polymyxin	O
B	O
.	O

In	O
the	I-protein
murine	O
macrophage	O
cell	O
line	I-protein
RAW	O
264.7	O
,	O
Treponema	O
culture	O
supernatants	O
induced	I-protein
TNF-alpha	B-protein
secretion	O
in	I-protein
a	I-protein
LPS	B-protein
binding	I-protein
protein	O
(	O
LBP	B-protein
)	O
-dependent	I-protein
fashion	O
.	O

To	O
enrich	O
for	I-protein
active	O
compounds	O
,	O
supernatants	O
were	O
extracted	O
with	I-protein
butanol	O
,	O
while	O
whole	O
cells	I-protein
were	O
extracted	O
using	O
a	I-protein
phenol/water	O
method	O
resulting	O
in	I-protein
recovery	O
of	I-protein
material	I-protein
exhibiting	O
a	I-protein
similar	O
activity	I-protein
profile	O
.	O

An	O
LPS-LBP	O
binding	I-protein
competition	O
assay	O
revealed	O
an	I-protein
interaction	I-protein
of	I-protein
the	I-protein
treponeme	O
phenol/water	O
extracts	O
with	I-protein
LBP	B-protein
,	O
while	O
precipitation	O
studies	O
implied	O
an	I-protein
affinity	I-protein
to	I-protein
polymyxin	O
B	O
and	I-protein
endotoxin	O
neutralizing	O
protein	O
.	O

Macrophages	O
obtained	O
from	I-protein
C3H/HeJ	O
mice	O
carrying	O
a	I-protein
Toll-like	B-protein
receptor	I-protein
(	O
TLR	O
)	O
-4	I-protein
mutation	I-protein
were	O
stimulated	O
with	I-protein
treponeme	O
extracts	O
for	I-protein
NO	I-protein
release	I-protein
to	I-protein
assess	O
the	I-protein
role	O
of	I-protein
TLRs	O
in	I-protein
cell	O
activation	I-protein
.	O

Furthermore	O
,	O
NF-kappaB	B-protein
translocation	O
in	I-protein
TLR-2-negative	O
Chinese	I-protein
hamster	I-protein
ovary	I-protein
(	O
CHO	O
)	O
cells	I-protein
was	O
studied	O
.	O

We	O
found	O
that	O
phenol/water-extracts	O
of	I-protein
the	I-protein
two	O
strains	O
use	O
TLRs	O
differently	O
with	I-protein
T.	I-protein
brennaborense-stimulating	O
cells	I-protein
in	I-protein
a	I-protein
TLR-4-dependent	O
fashion	O
,	O
while	O
T.	I-protein
maltophilum-mediated	O
activation	I-protein
apparently	O
involved	I-protein
TLR-2	O
.	O

These	O
results	O
indicate	O
the	I-protein
presence	O
of	I-protein
a	I-protein
novel	O
class	O
of	I-protein
glycolipids	O
in	I-protein
Treponema	O
initiating	O
inflammatory	O
responses	O
involving	O
LBP	B-protein
,	O
CD14	B-protein
,	O
and	I-protein
TLRs	O
.	O

###MEDLINE:20402338

Integration	O
of	I-protein
calcineurin	B-protein
and	I-protein
MEF2	O
signals	I-protein
by	I-protein
the	I-protein
coactivator	O
p300	B-protein
during	I-protein
T-cell	O
apoptosis	O
.	O

T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
-induced	O
thymocyte	B-protein
apoptosis	O
is	O
mediated	I-protein
by	I-protein
calcium-dependent	I-protein
signal	O
transduction	I-protein
pathways	O
leading	O
to	I-protein
the	I-protein
transcriptional	O
activation	I-protein
of	I-protein
members	O
of	I-protein
the	I-protein
Nur77	I-protein
family	I-protein
.	O

The	O
major	O
calcium-	O
and	I-protein
calcineurin-responsive	O
elements	O
in	I-protein
the	I-protein
Nur77	I-protein
promoter	I-protein
are	O
binding	I-protein
sites	I-protein
for	I-protein
myocyte	B-protein
enhancer	O
factor-2	I-protein
(	O
MEF2	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	O
T	O
cells	I-protein
(	O
NFAT	B-protein
)	O
interacts	I-protein
with	I-protein
MEF2D	B-protein
and	I-protein
enhances	O
its	O
transcriptional	O
activity	I-protein
,	O
offering	O
a	I-protein
plausible	O
mechanism	O
of	I-protein
activation	I-protein
of	I-protein
MEF2D	B-protein
by	I-protein
calcineurin	B-protein
.	O

We	O
report	O
here	O
that	O
NFATp	B-protein
synergizes	O
with	I-protein
MEF2D	B-protein
to	I-protein
recruit	O
the	I-protein
coactivator	O
p300	B-protein
for	I-protein
the	I-protein
transcription	O
of	I-protein
Nur77	I-protein
.	O

Surprisingly	O
,	O
the	I-protein
enhancement	O
of	I-protein
transcriptional	O
activity	I-protein
of	I-protein
MEF2D	B-protein
by	I-protein
NFATp	B-protein
does	O
not	I-protein
require	O
its	O
DNA-binding	O
activity	I-protein
,	O
suggesting	O
that	O
NFATp	B-protein
acts	O
as	O
a	I-protein
coactivator	O
for	I-protein
MEF2D	B-protein
.	O

Transient	I-protein
co-expression	O
of	I-protein
p300	B-protein
,	O
MEF2D	B-protein
,	O
NFATp	B-protein
and	I-protein
constitutively	O
active	O
calcineurin	B-protein
is	O
sufficient	O
to	I-protein
recapitulate	O
TCR	O
signaling	O
for	I-protein
the	I-protein
selective	O
induction	I-protein
of	I-protein
the	I-protein
endogenous	O
Nur77	I-protein
gene	O
.	O

These	O
results	O
implicate	O
NFAT	B-protein
as	O
an	I-protein
important	O
mediator	O
of	I-protein
T-cell	O
apoptosis	O
and	I-protein
suggest	O
that	O
NFAT	B-protein
is	O
capable	O
of	I-protein
integrating	O
the	I-protein
calcineurin	O
signaling	O
pathway	I-protein
and	I-protein
other	O
pathways	O
through	I-protein
direct	O
protein-protein	O
interaction	I-protein
with	I-protein
other	O
transcription	B-protein
factors	I-protein
.	O

###MEDLINE:20400243

Induction	O
or	I-protein
suppression	O
of	I-protein
a	I-protein
B	O
cell-specific	I-protein
response	I-protein
to	I-protein
self	B-protein
antigen	I-protein
in	I-protein
vivo	O
is	O
dependent	I-protein
upon	O
dendritic	B-protein
cell	O
activation	I-protein
via	I-protein
the	I-protein
TNF-alpha	B-protein
receptor	I-protein
at	I-protein
the	I-protein
time	O
of	I-protein
antigen	O
uptake	I-protein
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	I-protein
retinal	B-protein
autoantigen	I-protein
,	O
S-antigen	B-protein
,	O
contains	I-protein
a	I-protein
functional	O
TNF-alpha	B-protein
homologous	I-protein
domain	I-protein
which	O
stimulates	O
maturation	I-protein
and	I-protein
differentiation	I-protein
of	I-protein
cultured	O
dendritic	B-protein
cells	I-protein
(	O
DC	O
)	O
or	I-protein
tissue	O
DC	O
via	I-protein
the	I-protein
p55	O
TNF-alpha	B-protein
receptor	I-protein
.	O

Tissue	O
DC	O
became	O
more	O
dendritiform	O
in	I-protein
shape	O
,	O
and	I-protein
migrated	O
into	O
culture	O
supernatant	O
.	O

S-antigen	B-protein
also	O
stimulated	O
accumulation	I-protein
of	I-protein
cell	B-protein
surface	I-protein
MHC	I-protein
class	I-protein
II	I-protein
antigen	I-protein
with	I-protein
a	I-protein
corresponding	O
loss	O
of	I-protein
acidic	O
intracellular	I-protein
vesicles	O
,	O
and	I-protein
induced	I-protein
IL-1beta	B-protein
and	I-protein
IL-12	O
mRNA	O
expression	I-protein
in	I-protein
cultured	O
bone	O
marrow-derived	O
DC	O
.	O

In	O
addition	O
,	O
cultured	O
splenic	O
DC	O
primed	O
immune	O
responses	O
to	I-protein
S-antigen	B-protein
in	I-protein
vivo	O
in	I-protein
the	I-protein
absence	I-protein
of	I-protein
other	O
,	O
exogenous	B-protein
cytokine	I-protein
sources	O
.	O

DC	O
pulsed	O
with	I-protein
either	O
retinal	O
S-antigen	B-protein
or	I-protein
another	O
retinal	B-protein
autoantigen	I-protein
,	O
interphotoreceptor	B-protein
retinoid	B-protein
binding	I-protein
protein	I-protein
(	O
IRBP	B-protein
)	O
,	O
were	O
able	O
to	I-protein
stimulate	O
naive	O
T	O
cell	O
proliferation	I-protein
in	I-protein
vitro	O
,	O
but	O
only	I-protein
S-antigen	B-protein
-pulsed	O
DC	O
were	O
able	O
to	I-protein
induce	O
an	I-protein
immune	O
response	I-protein
in	I-protein
vivo	O
and	I-protein
initiate	O
antibody	I-protein
class	O
switching	O
.	O

In	O
contrast	O
,	O
IRBP	B-protein
-pulsed	O
DC	O
had	O
no	I-protein
detectable	O
in	I-protein
vivo	O
priming	O
effect	O
and	I-protein
IgG	I-protein
antibody	I-protein
levels	I-protein
remained	O
suppressed	I-protein
even	O
after	O
immunization	O
with	I-protein
IRBP	B-protein
in	I-protein
complete	O
Freund	O
's	I-protein
adjuvant	O
.	O

These	O
results	O
indicate	O
that	O
DC	O
from	I-protein
the	I-protein
same	O
precursor	I-protein
population	O
can	O
either	O
induce	O
or	I-protein
suppress	O
a	I-protein
B	O
cell-specific	I-protein
response	I-protein
to	I-protein
self	B-protein
antigen	I-protein
in	I-protein
vivo	O
,	O
the	I-protein
outcome	O
being	O
dependent	I-protein
upon	O
DC	O
activation	I-protein
at	I-protein
the	I-protein
time	O
of	I-protein
antigen	O
uptake	I-protein
